T1181

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

Lanopepden (GSK 1322322) is a potent peptide deformylase inhibitor effective against Staphylococcus aureus strains ATCC 29213 and ATCC 25923, and is applicable in the study of pneumonia, dermatological, and infectious diseases.

L791943 is a selective, potent) inhibitor of Phosphodiesterase-4 (PDE4,IC50 of 4.2 nM).

Laetanine, exhibits antiplasmodial activity, a noraporphine alkaloid from Litsea laeta.

L-Eflornithine is an irreversible ornithine decarboxylase (ODC) inhibitor with a KD of 1.3±0.3 μM, and a Kinact of 0.15±0.03 min-1. L-Eflornithine is an enantiomer of Eflornithine.

L-Eflornithine is an irreversible ornithine decarboxylase (ODC) inhibitor with a KD of 1.3±0.3 µM, and a Kinact of 0.15±0.03 min-1. L-Eflornithine monohydrochloride (L-DFMO monohydrochloride) is an enantiomer of Eflornithine.

Laflunimus (HR325) is a DHODH inhibitor that inhibits immunoglobulin IgM and IgG secretion in vitro and in vivo, with an IC50=2.5 μm, and exerts an immunosuppressive effect by interfering with pyrimidine metabolism, and is used in the study of neuralgia.

Lamivudine 13C,15N2, an impurity of Lamivudine (BCH-189), functions as an inhibitor of both HIV-1/2 reverse transcriptase and hepatitis B virus reverse transcriptase, classifying it as a nucleoside reverse transcriptase inhibitor (NRTIs).

Lansoprazole D4 (AG-1749 D4) is a deuterium labeled Lansoprazole. Lansoprazole is an inhibitor of proton pump which prevents the stomach from producing acid.

Lansoprazole Sulfide D4 is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 μM intracellularly and 0.46 μM in broth.Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole.

LAS191954 is a selective, potent and orally active PI3Kδ inhibitor for inflammatory diseases treatment(IC50 : 2.6 nM).

Lascufloxacin, a potent and orally active fluoroquinolone antibacterial agent, holds potential for the treatment of various infectious diseases, including lower respiratory tract infections. It effectively inhibits infections caused by a wide range of pathogens, encompassing those resistant to quinolones.

Gefitinib hydrochloride (ZD-1839 hydrochloride) is an orally active selective and potent tyrosine kinase (EGFR) inhibitor. Gefitinib hydrochloride exhibits antitumor activity, selectively inhibits EGF-stimulated tumor cell growth, induces cellular autophagy, improves lung dysfunction, and inhibits inflammation. Gefitinib hydrochloride has antitumor activity, selectively inhibits EGF-stimulated tumor cell growth, induces cellular autophagy, ameliorates lung dysfunction, and inhibits the progression of inflammation and fibrosis.